Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kevin Shandera

Urology Rancho Mirage, CA Medical Doctor

NPI 1447298567 CMS profile 19781

39000 Bob Hope Dr, Rancho Mirage, CA 92270

Open in the dashboard

General payments

$631

11 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kevin Shandera of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $631 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $164 1
2022 General $91 2
2021 General $14 1
2020 General $35 2
2019 General $327 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Shandera
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kevin Shandera were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kevin Shandera Urology median Middle half National median
2019 $327 $480 $147–$1,201 $163
2020 $35 $246 $87–$645 $114
2021 $14 $358 $111–$1,000 $132
2022 $91 $476 $143–$1,263 $149
2023 $164 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boston Scientific Corporation $273 3 payments
  2. Agiliti Surgical, Inc. $179 1 payment
  3. Bayer HealthCare Pharmaceuticals Inc. $57 1 payment
  4. Allergan Inc. $51 3 payments
  5. Astellas Pharma US Inc $37 2 payments
  6. Ambu Inc. $34 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $631 11 payments
Products named General payments · program years 2019–2023
  1. Solyx SIS System $164 1 payment
  2. ACCUMAX $109 2 payments
  3. Nubeqa $57 1 payment
  4. BOTOX Hyperhydrosis $39 2 payments
  5. MYRBETRIQ $37 2 payments
  6. BOTOX Urology $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,958

Median for Urology: 1,053

Drug cost

$659,842

Median for Urology: $101,464

Branded share of claims

35%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 430 $463,305
Gemtesa Vibegron Brand 100 $115,835
Tamsulosin Hcl Generic 877 $16,755
Mirabegron Er Mirabegron Brand 20 $13,212
Potassium Citrate Er Potassium Citrate Brand 121 $10,027
Finasteride Generic 570 $8,520
Methenamine Hippurate Generic 40 $4,647
Estradiol Generic 53 $3,771
Bethanechol Chloride Generic 15 $2,825
Tolterodine Tartrate Er Tolterodine Tartrate Brand 14 $2,576

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$292,730

Medicare's payments for the services billed

Medicare patients

1,318

Average age 78

Services billed

3,937

639 women, 679 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 38%
Chronic kidney disease 32%
Diabetes 25%
Depression 25%
Atrial fibrillation 24%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record